StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Get Free Report) in a research note issued on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Up 3.6 %
Shares of NASDAQ:EVOK opened at $5.53 on Friday. Evoke Pharma has a fifty-two week low of $3.54 and a fifty-two week high of $17.88. The firm has a 50-day simple moving average of $4.81 and a 200 day simple moving average of $5.59. The company has a market cap of $47.54 million, a PE ratio of -3.02 and a beta of 0.39.
Evoke Pharma (NASDAQ:EVOK – Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.21). Evoke Pharma had a negative net margin of 86.74% and a negative return on equity of 964.25%. The business had revenue of $2.55 million for the quarter.
Evoke Pharma Company Profile
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Further Reading
- Five stocks we like better than Evoke Pharma
- Bank Stocks – Best Bank Stocks to Invest In
- Survey Reveals: America’s Most Coveted Businesses in 2024
- How to Read Stock Charts for Beginners
- Top 3 Stocks to Play Oil’s Potential Comeback Rally
- Why Invest in High-Yield Dividend Stocks?
- Analysts See Growth in CrowdStrike Stock Despite July Setback
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
